Exploring windows to enhance shareholder value: Thyrocare Technologies

Media reports suggested Pharmeasy, an online pharmacy, was looking to acquire Thyrocare Technologies for Rs 7,000 crore.
Amid reports that suggested Pharmeasy was looking to acquire a stake in A Velumani-led diagnostics player Thyrocare, the latter clarified to the stock exchanges on Thursday that it “keeps exploring” opportunities to enhance shareholder value.


In a statement to the BSE, Thyrocare said, "The company during its normal course of business keeps exploring various opportunities to enhance shareholder value."


Earlier in the day, media reports suggested Pharmeasy, an online pharmacy, was looking to acquire Thyrocare Technologies for Rs 7,000 crore.


Thyrocare's market capitalisation is around Rs 6,916 crore. The deal thus could be for a shareholding in the firm. The report further claimed that through the deal, the Thyrocare promoters were looking to offload a stake that is likely to trigger an open offer for shareholders.


The promoters held a 66.14 per cent stake in Thyrocare as of March. Thyrocare posted a revenue of Rs 474 crore in FY21.      

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel